Exact Mass: 1009.4049052

Exact Mass Matches: 1009.4049052

Found 13 metabolites which its exact mass value is equals to given mass value 1009.4049052, within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error 0.01 dalton.

SJF-0628 (compound 512) is a PROTAC RAF degrader. SJF-0628 induces targeted degradation of BRAF mutants (DC50: 5.4 nM, 4.64 nM, 15.5 nM, 2.11 nM, 63.9 nM for BRAF V600E, V600K, G464V, G469A, K601E respectively). SJF-0628 has anti-tumor activity. SJF-0628 can be used for research of disorders that result from aggregation or accumulation of RAF, or the constitutive activation of RAF[1].

n-[(2s,5s,11s,12s,15s,18s,21r)-15-(3-carbamimidamidopropyl)-2-[(4-chlorophenyl)methyl]-6,13,16,21-tetrahydroxy-5-[(4-hydroxyphenyl)methyl]-4,11-dimethyl-3,9,22-trioxo-8-(sec-butyl)-10-oxa-1,4,7,14,17-pentaazabicyclo[16.3.1]docosa-6,13,16-trien-12-yl]-2-hydroxy-3-(sulfooxy)propanimidic acid

n-[(2s,5s,11s,12s,15s,18s,21r)-15-(3-carbamimidamidopropyl)-2-[(4-chlorophenyl)methyl]-6,13,16,21-tetrahydroxy-5-[(4-hydroxyphenyl)methyl]-4,11-dimethyl-3,9,22-trioxo-8-(sec-butyl)-10-oxa-1,4,7,14,17-pentaazabicyclo[16.3.1]docosa-6,13,16-trien-12-yl]-2-hydroxy-3-(sulfooxy)propanimidic acid

C43H60ClN9O15S (1009.3617919999999)

2-({[(2s,3r,4r,5r)-5-(aminomethyl)-4-hydroxy-3-(sulfooxy)oxolan-2-yl]oxy}[(2s,3s,4r,5r)-3,4-dihydroxy-5-(4-hydroxy-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl)-6-({3-[(4-carboxy-3-methylbutanoyl)oxy]tetradecanoyl}oxy)-1,4-dimethyl-3-oxo-1,4-diazepane-5-carboxylic acid

2-({[(2s,3r,4r,5r)-5-(aminomethyl)-4-hydroxy-3-(sulfooxy)oxolan-2-yl]oxy}[(2s,3s,4r,5r)-3,4-dihydroxy-5-(4-hydroxy-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl)-6-({3-[(4-carboxy-3-methylbutanoyl)oxy]tetradecanoyl}oxy)-1,4-dimethyl-3-oxo-1,4-diazepane-5-carboxylic acid

C42H67N5O21S (1009.4049052)

2-({[(2s,3r,4r,5r)-5-(aminomethyl)-4-hydroxy-3-(sulfooxy)oxolan-2-yl]oxy}[(2s,3s,4r,5r)-3,4-dihydroxy-5-(4-hydroxy-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl)-6-({3-[(4-carboxy-3-methylbutanoyl)oxy]-12-methyltridecanoyl}oxy)-1,4-dimethyl-3-oxo-1,4-diazepane-5-carboxylic acid

2-({[(2s,3r,4r,5r)-5-(aminomethyl)-4-hydroxy-3-(sulfooxy)oxolan-2-yl]oxy}[(2s,3s,4r,5r)-3,4-dihydroxy-5-(4-hydroxy-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl)-6-({3-[(4-carboxy-3-methylbutanoyl)oxy]-12-methyltridecanoyl}oxy)-1,4-dimethyl-3-oxo-1,4-diazepane-5-carboxylic acid

C42H67N5O21S (1009.4049052)

2-({[5-(aminomethyl)-4-hydroxy-3-(sulfooxy)oxolan-2-yl]oxy}[3,4-dihydroxy-5-(4-hydroxy-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl)-6-({3-[(4-carboxy-3-methylbutanoyl)oxy]tetradecanoyl}oxy)-1,4-dimethyl-3-oxo-1,4-diazepane-5-carboxylic acid

2-({[5-(aminomethyl)-4-hydroxy-3-(sulfooxy)oxolan-2-yl]oxy}[3,4-dihydroxy-5-(4-hydroxy-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl)-6-({3-[(4-carboxy-3-methylbutanoyl)oxy]tetradecanoyl}oxy)-1,4-dimethyl-3-oxo-1,4-diazepane-5-carboxylic acid

C42H67N5O21S (1009.4049052)

n-[15-(3-carbamimidamidopropyl)-2-[(4-chlorophenyl)methyl]-6,13,16,21-tetrahydroxy-5-[(4-hydroxyphenyl)methyl]-4,11-dimethyl-3,9,22-trioxo-8-(sec-butyl)-10-oxa-1,4,7,14,17-pentaazabicyclo[16.3.1]docosa-6,13,16-trien-12-yl]-2-hydroxy-3-(sulfooxy)propanimidic acid

n-[15-(3-carbamimidamidopropyl)-2-[(4-chlorophenyl)methyl]-6,13,16,21-tetrahydroxy-5-[(4-hydroxyphenyl)methyl]-4,11-dimethyl-3,9,22-trioxo-8-(sec-butyl)-10-oxa-1,4,7,14,17-pentaazabicyclo[16.3.1]docosa-6,13,16-trien-12-yl]-2-hydroxy-3-(sulfooxy)propanimidic acid

C43H60ClN9O15S (1009.3617919999999)